Sign in
Explore the registryTrack Elzovantinib's trials

SHIELD-1

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

Elzovantinib (TPX-0022)OngoingActive not recruitingPhase 1Open NCT03993873 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…